

Product Data Sheet

Anatumomab mafenatox

Cat. No.: HY-P99436 **CAS No.:** 1370261-50-9

Target: Others
Pathway: Others

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Anatumomab mafenatox (ABR-214936) is a 73 KDa recombinant protein to recognize the tumor-associated antigen 5T4, which is widely expressing in malignancy. Anatumomab mafenatox is between a modified form of SEA and a murine Fab. The main side effects of Anatumomab mafenatox are reported to include fever, low blood pressure, pain, nausea and drowsiness ^[1] .
IC ₅₀ & Target	5T4 ^[1]

REFERENCES

[1]. Shaw DM, et al. A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

 ${\tt Address: 1\ Deer\ Park\ Dr, Suite\ Q, Monmouth\ Junction, NJ\ 08852, USA}$

Inhibitors •

Screening Libraries

Proteins